LIXT.OB Insider Trading Activity and SEC Form 4 Filings
LIXT.OB insider trading summary
No open-market insider purchases or sales of Lixte Biotechnology Holdings, Inc. (LIXT.OB) have been reported on SEC Form 4 in the past 12 months.
Latest LIXT.OB insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 7, 2018 | Stephen J. Forman | Director | Buy | $50K (100,000 @ $0.50) |
| Dec 7, 2018 | Gil Schwartzberg | 10% Owner | Buy | $520K (1,040,000 @ $0.50) |
| Dec 7, 2018 | Arthur Riggs | 10% Owner | Buy | $630K (1,260,000 @ $0.50) |
| Dec 7, 2018 | Jane Merrill Riggs | 10% Owner | Buy | $630K (1,260,000 @ $0.50) |
| Dec 7, 2018 | Philip F Palmedo | Director | Buy | $50K (100,000 @ $0.50) |
| Feb 19, 2016 | Eric Forman | 10% Owner | Buy | $3K (10,000 @ $0.30) |
| Feb 17, 2016 | Eric Forman | 10% Owner | Buy | $13K (43,500 @ $0.30) |
| Feb 4, 2016 | Eric Forman | 10% Owner | Buy | $625 (2,500 @ $0.25) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.